Search Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupTumor, regardless of entityDiseaseOccult Primary CarcinomaSubgroupunfavorable prognosisICD10C80.0MeSHNeoplasms, Unknown PrimarySequenceChemotherapyChemo-substanceCapecitabineCarboplatinCisplatinDocetaxelEtoposideGemcitabineIrinotecanNivolumabOxaliplatinPaclitaxelPembrolizumabChemo-substanceCapecitabineCarboplatinCisplatinDocetaxelEtoposideGemcitabineIrinotecanNivolumabOxaliplatinPaclitaxelPembrolizumabChemo-substanceCapecitabineCarboplatinCisplatinDocetaxelEtoposideGemcitabineIrinotecanNivolumabOxaliplatinPaclitaxelPembrolizumabChemo-substanceCapecitabineCarboplatinCisplatinDocetaxelEtoposideGemcitabineIrinotecanNivolumabOxaliplatinPaclitaxelPembrolizumabNo. Substances12 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfatePegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfatePegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfatePegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfatePegfilgrastimPotassium chlorideNo. Substances135678Protocol classificationTherapy classificationalternativecurrent standardempirical, modifiedIntensityStandard doseTherapy indicationFirst lineSecond lineseveral possibleTherapy phaseTherapy intentionpalliativeRisksAllergic ReactionAlopeciaAnemia Hb below 8g/dlAnemia Hb below 10g/dlAstheniaCardiotoxicityColitisConstipationDiarrheaEmetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaHepatotoxicityHyperthyroidismHypothyroidismIncrease AminotransferasesInfectionsMyalgiasNauseaNephritisNeuropathyNeurotoxicityNeutropeniaPneumonitisPyrexiaRashRenal FailureThrombocytopenia below 50 000/µl only studiesPublicationAuthorBerry WBriasoulis ABriasoulis EFizazi KGross-Goupil MHainsworth JHainsworth JDHuebner GPentheroudakis GPouessel DRaghav KPTanizaki JDiseaseAdeno-, gering diff. oder gerin diff. Plattenepithel-CUP, ECOG 0-2Adeno-, gut oder gering diff. , ECOG 0-2, ErstlinieAdeno- und undiff. metastasiertes CUP, ECOG 0-2, ErstlinieCUP, nach platinhaltiger Chemotherapie, ECOG 0-1CUP Syndrom, ECOG 0-2, ErstlinieCUP Syndrom mit guter Prognose, ECOG 0-1, ErstlinieKarzinom bei unbekanntem Primärkarzinom, Erstlinie, ECOG 0-1Karzinom bei unbekanntem Primärkarzinom, Patienten mit ungünstiger Prognose, niedrige Tox., ErstlinieKarzinom bei unbekanntem Primärtumor, Erstlinie, ECOG 0-2Karzinom bei unbekanntem Primärtumor, metastasiert, nicht lokal therapierbar, poor risk, Erstlinie, ECOG 0-2Karzinom bei unbekanntem Primärtumor, mindestens 1 Vortherapie, ECOG 0-1Karzinom bei unbekanntem Primärtumor, Zweitlinie, ECOG 0-2metastasiertes Karzinom bei unbekanntem Primärtumor, Erstlinie, ECOG 0-2OriginDepartment of Medical Oncology, Centre Regional de Lutte contre le Cancer Val d´Aurelle, Montpellier, FranceDepartments of Medical Oncology, Ioannina University Hospital, Hellenic Cooperative Oncology Group StudyESMO Guidelines 2015GEFCAPI 02 Trial, Institut Gustave Roussy, University of Paris Sud, Villejuif, FranceInstitut Gustave Roussy, University of Paris Sud, Villejuif, France, GEFCAPI 02Ioannina University Hospital, Ioannina, Greece, Hellenic Cooperative Oncology GroupIoannina University Hospital, Ioannina, Greece, Hellenic cooperative oncology group studyKindai University Faculty of Medicine, OsakasayamaSarah Cannon Oncology Research ConsortiumSarah Cannon Research Institute, Nashville, TN, USAThe German CUP Study GroupThe University of Texas MD Anderson Cancer Center, Houston, TexasUS Oncology Research, Inc., Houston, Texas, USAProtocols in Revision 13 protocols foundProtocols under revision.Capecitabine 1000 / Oxaliplatin 130, Carcinoma in an Occult Primary (PID1190 V1.1)Cisplatin 100 / Gemcitabine 1250, Carcinoma of Unknown Primary (PID618 V1.1)Cisplatin 75 / Etoposide 100, Carcinoma of Unknown Primary (PID1186 V1.1)Cisplatin 75 / Gemcitabine 1250, Carcinoma in Occult Primary (PID1187 V1.1)Docetaxel 75 / Carboplatin 5, Carcinoma with Occult Primary unknown (PID1188 V1.0)Gemcitabine 1000 / Docetaxel 75, Carcinoma of Unknown Primary (PID617 V1.0)Irinotecan 100 / Gemcitabine 1000, Carcinoma of Unknown Primary (PID515 V1.0)Nivolumab 240, Carcinoma of Unknown Primary (PID1967 V1.0)Oxaliplatin 80 / Irinotecan 160, Carcinoma in Unknown Primary (PID1189 V1.0)Paclitaxel 175 / Carboplatin 5, Carcinoma of Unknown Primary (PID514 V1.2)Paclitaxel 200 / Carboplatin 6, Carcinoma in Occult Primary (PID1192 V1.1)Paclitaxel 80 / Carboplatin 2, Carcinoma of Unknown Primary (PID568 V1.2)Pembrolizumab 200, Carcinoma of Unknown Primary (PID2426 V1.0)
